Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408732 | 0.82 | ADORA3 (0.59) | FLT3ADORA3HIF1AEGFRSMN1; SMN2 | |
| SCHEMBL5408035 | 0.82 | FLT3 (0.69) | FLT3ADORA3HIF1ANPC1ALDH1A1 | |
| SCHEMBL12271835 | 0.81 | FLT3 (0.68) | FLT3ADORA3HIF1AKDM4EHSD17B10 | |
| SCHEMBL12271994 | 0.81 | FLT3 (1.00) | FLT3ADORA3 | |
| SCHEMBL12273036 | 0.80 | FLT3 (0.67) | FLT3ADORA3HIF1AHSD17B10FYN | |
| SCHEMBL12272668 | 0.79 | FLT3 (1.00) | FLT3ADORA3 | |
| SCHEMBL12272948 | 0.78 | FLT3 (1.00) | FLT3ADORA3HIF1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12522896 | 0.77 | FLT3 (0.64) | FLT3ADORA3 | |
| Hydrochloric Acid SCHEMBL12273240 | 0.77 | FLT3 (0.63) | FLT3ADORA3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL12273239 | 0.77 | FLT3 (0.63) | FLT3ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686319-B1 | IMIDAZO PYRAZINES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2686319-B1 | IMIDAZO PYRAZINES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8673905-B2 | Imidazo pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673905-B2 | Imidazo pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2686319-A1 | IMIDAZO PYRAZINES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20120238564-A1 | IMIDAZO PYRAZINES | LUK KIN-CHUN (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123470-A1 | IMIDAZO PYRAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238564-A1 | IMIDAZO PYRAZINES | LUK KIN-CHUN (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123470-A1 | IMIDAZO PYRAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238564-A1 | IMIDAZO PYRAZINES | THPO, MCL1, IKZF3 | FLT3 5/4885ADORA3 2926/4885HIF1A 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.